An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Terns Pharmaceuticals to participate in upcoming investor conferences
Positive
None.
Negative
None.
FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of management will be participating in the following upcoming investor conferences:
H.C. Wainwright 7th Annual NASH Virtual Investor Conference Date/Time: Tuesday, October 24, 2023 at 2:30 PM ET Format: Fireside Chat Location: Virtual
UBS Biopharma Conference Date/Time: Wednesday, November 8, 2023 at 4:30 PM ET Format: Fireside Chat Location: Miami Beach, FL
Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns’ pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-β agonist, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.
Terns Pharmaceuticals will be participating in the H.C. Wainwright 7th Annual NASH Virtual Investor Conference and the UBS Biopharma Conference.
The H.C. Wainwright 7th Annual NASH Virtual Investor Conference will take place on Tuesday, October 24, 2023 at 2:30 PM ET, and the UBS Biopharma Conference will take place on Wednesday, November 8, 2023 at 4:30 PM ET.
The H.C. Wainwright 7th Annual NASH Virtual Investor Conference will be held virtually, and the UBS Biopharma Conference will be held in Miami Beach, FL.
Yes, there will be live webcasts of the fireside chats available on the investor relations page of the Terns Pharmaceuticals website.
Yes, replays of the webcasts will be archived on Terns' website for at least 30 days following the presentations.
terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.
